EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer
EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2013.11.023
复制
发表时间：
2014-02-01
期刊：
影响因子：
5.3
通讯作者：
Meldgaard, Peter
中科院分区：
文献类型：
--
作者：
Weber, Britta;Hager, Henrik;Meldgaard, Peter
Objectives: In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal growth factor receptor (EGFR) mutations in an unselected population of Danish patients with non-small cell lung cancer offered treatment with erlotinib, mainly in second-line.Materials and methods: Four hundred and eighty eight patients with advanced NSCLC were included. The mutation status was assessed using the cobas (R) EGFR Mutation Test. Erlotinib was administrated (150 mg/d) until disease progression or unacceptable toxicities occurred. The primary endpoint was progression-free survival. Secondary endpoints were overall survival and response.Results: Biopsies were retrieved from 467 patients, and mutation results obtained for 462. We identified 57(12%) patients with EGFR mutations: 33 exon 19 deletions, 13 exon 21 mutations, 5 exon 18 mutations, 3 exon 20 insertions, 1 exon 20 point mutation (S768I), and two complex mutations. Seven percent of the patients were never smokers. The differences in median progression-free survival and overall survival between the mutated group and the wild-type group were 8.0 vs. 2.5 months, p
